Footer Menu

Contact

Privacy Policy

Cookie Policy

Legal Notice

ucb.com

Legal Statement Links

Letter to our stakeholders

Our purpose

Therapeutic focus

Sustainable business

Key figures

UCB IAR 2024 ENG.pdf

DesktopLogo.svg

MobileLogo.svg

2024 Overview

Creating value for patients, now and into the future

Purpose & Strategy

Driving sustainable business that improves people’s lives

UCB’s performance

Management

Deep dive into our 2024 data & reporting tables

Data & Reporting

This document contains information on investigational drug products that have not been approved for any use by any authority in the world or information on new indications for approved products. The safety and efficacy of these investigational drug products or new indications has yet to be established. For approved drugs, prescribing information may vary from country to country.

Disclaimer

UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology. We work with the patients and the scientific community to find new treatments, while continuing to improve the well-being of people with chronic disease.

large_videoPlaceholder.jpg

medium_videoPlaceholder.jpg

small_videoPlaceholder.jpg

thumbnail_videoPlaceholder.jpg

videoPlaceholder.jpg

Integrated Annual Report 2024

family_rgb_header_fv.webp

Header_Mobile_v2.webp

Inspired by patients. Driven by science.

20241218_ucb_071_v4.webp

We are proud of what our ambition has allowed us to achieve over the last year, for UCB and for all our stakeholders. Inspired by the patients we serve and the science we practice, 2024 has seen us focus on creation: of innovative solutions, of trusted partnerships, and most of all, the creation of transformative value for people living with severe diseases and their caregivers, so that they can live the best life that they can, unburdened by disease.

‘Inspired by patients, driven by science’ – never has that message felt more relevant to all of us at UCB than it does right now. 

To create sustainable impact for people living with severe disease and society at large, we advance science across immunology and neurology and make informed choices to address unmet patient needs, improve health equity, minimize our environmental footprint and optimize shareholder value.

We create value for patients, now and into the future.

Who is UCB_.mp4

Still_1.14.4.png

We aim to elevate lives through our medicines, leveraging our unique insights and collaborative approaches to develop groundbreaking treatments that significantly improve the quality of life for people with severe diseases. 

We are driven by our commitment to people living with severe diseases who inspire our research and development across neurology, immunology, and other areas where our expertise, innovation, and ambition align with unmet needs.

Our business approach takes a long-term view of how we will bring positive impact for people living with severe diseases, our colleagues and communities, our shareholders and the planet. This integrated approach to drive sustainable growth guides how we do business, with future generations in mind.

At UCB, sustainability is at the core of our strategy and our performance. 

Access coverage achieved for UCB medicines

Net sales increased to €5 613 million, a plus of 15% (+17% CER). This growth was driven by the strong, triple- and double-digit performance of UCB’s growth drivers: BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO® and ZILBRYSQ® as well as the solid performance from CIMZIA® and the strong contribution from BRIVIACT®, reaching its peak sales target of “at least €600 million” well ahead of the 2026 target. 
 
**Net Sales by product** 
## **Immunology** 
- CIMZIA® €2,033 M 
- BIMZELX® €607 M 
- EVENITY® €103 M 

**Neurology** 
- BRIVIACT® €686 M 
- KEPPRA® (including KEPPRA® XR / E KEPPRA®) €582 M 
- FINTEPLA® €340 M 
- VIMPAT® €329 M 
- RYSTIGGO® €202 M 
- NAYZILAM® €124 M 
- ZILBRYSQ® €72 M 
**Established Brands** € 577 M

€5 613 M Net sales 

Other revenue went up to €461 million or by 50%, driven by the successful completion of the sale of rights of two established brands, Atarax® and Nootropil® for Europe and selected countries in Latin-America and Asia-Pacific to ADVANZ PHARMA in November 2024, leading to other revenue of €157 million. 
 
Contract manufacturing sales decreased to €79 million from €119 million, due to lower demand for contract manufacturing and the expiration of agreements, mostly linked to the sale of established brands in 2023. “Other” revenue increased to €382 million driven by the proceeds from the above-mentioned sale of products. It also includes partnership activities in Japan (FINTEPLA®), continued milestones and other payments from R&D and licensing partners, including from Biogen for _dapirolizumab pegol_ in lupus (SLE, phase 3 program), Roche for _bepranemab_ in Alzheimer’s disease and Novartis on the development of _minzasolmin_ in Parkinson’s disease.

€461 M Other revenue 

In 2024, royalty income and fees remained relatively stable with €78 million after €77 million in 2023. The biotechnology IP income represents royalties on marketed products using UCB’s antibody intellectual property. “Other” includes royalties from UCB’s allergy portfolio and royalties on partnered or out-licensed products developed by UCB.

€78 M Royalty income and fees 

Our business approach continues to be rooted in innovation and sustainability, to make a meaningful difference for people living with severe diseases, while delivering the financial return expected by our shareholders.

Our performance in 2024

Rectangle_221_42b700428c.png

Download the UCB Investor Relations app

Contact us

**UCB SA is located at Allée de la Recherche, 60 – 1070 Brussels, Belgium. For general enquiries, contact us on +32 2 559 99 99.**
\
For other enquiries, please contact your closest UCB location or one of the contact points below. 

###### **Investor relations**
###### **Antje Witte**, Head of Investor Relations
E-mail: [Antje.Witte@ucb.com](mailto:Antje.Witte@ucb.com)

###### **Sahar Yazdian**, Investor Relations Lead
E-mail: [Sahar.Yazdian@ucb.com](mailto:Sahar.Yazdian@ucb.com)

Google_Play_Store_badge_EN.png

Download_on_the_App_Store_Badge.png

**Gwendoline Ornigg**, Head of Global Corporate Communication 
E-mail: [gwendoline.ornigg@ucb.com](mailto:gwendoline.ornigg@ucb.com?)

The full list of UCB corporate communications contact points can be found [here](https://www.ucb.com/stories-media/Contact). Please note that the UCB media relations team responds to calls and emails from professional journalists only.

Communications

**Veronique Toully**, Head of Sustainability, Corporate Affairs and Risk 
E-mail: [veronique.toully@ucb.com](mailto:veronique.toully@ucb.com?)

Sustainability 

Keen to make your mark for patients? Find out more about working for UCB [here](https://careers.ucb.com/global/en).  